Current status of pancreatic cancer with oligometastasis.

IF 0.5 4区医学 Q4 SURGERY Cirugia Y Cirujanos Pub Date : 2023-01-01 DOI:10.24875/CIRU.22000364

Óscar Chapa-Azuela, María J Corona-Torres, Edwin A Ayala-Moreno, Paola S Arroyo-Paredes, Eduardo Pérez-Torres, Alejandro Rodríguez-Báez, Eduardo E Montalvo-Javé

{"title":"Current status of pancreatic cancer with oligometastasis.","authors":"Óscar Chapa-Azuela, María J Corona-Torres, Edwin A Ayala-Moreno, Paola S Arroyo-Paredes, Eduardo Pérez-Torres, Alejandro Rodríguez-Báez, Eduardo E Montalvo-Javé","doi":"10.24875/CIRU.22000364","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic cancer is the seventh leading cause of death worldwide, with ductal adenocarcinoma as the most frequent neoplasm. Half of the patients who are diagnosed have metastases at the time of diagnosis.Objective: A review of the treatment of resectable pancreatic adenocarcinoma with oligometastatic disease was carried out in order to present an overview of the existing evidence.Method: A bibliographic search was carried in PubMed/Medline, Clinical Key and Index Medicus vhith MESH terms, from the year 1993 to 2022.Results: Patients with liver or lung metastases due to pancreatic ductal adenocarcinoma who undergo surgery and chemotherapy have a longer survival in carefully selected patients.Conclusions: The evidence regarding surgery in patients with pancreatic ductal adenocarcinoma and oligometastasis is limited and further randomized controlled trials are needed for both scenarios. As well as established criteria that help the selection of patients who can receive this type of treatment.","PeriodicalId":50990,"journal":{"name":"Cirugia Y Cirujanos","volume":"91 2","pages":"262-267"},"PeriodicalIF":0.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia Y Cirujanos","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/CIRU.22000364","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pancreatic cancer is the seventh leading cause of death worldwide, with ductal adenocarcinoma as the most frequent neoplasm. Half of the patients who are diagnosed have metastases at the time of diagnosis.

Objective: A review of the treatment of resectable pancreatic adenocarcinoma with oligometastatic disease was carried out in order to present an overview of the existing evidence.

Method: A bibliographic search was carried in PubMed/Medline, Clinical Key and Index Medicus vhith MESH terms, from the year 1993 to 2022.

Results: Patients with liver or lung metastases due to pancreatic ductal adenocarcinoma who undergo surgery and chemotherapy have a longer survival in carefully selected patients.

Conclusions: The evidence regarding surgery in patients with pancreatic ductal adenocarcinoma and oligometastasis is limited and further randomized controlled trials are needed for both scenarios. As well as established criteria that help the selection of patients who can receive this type of treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胰腺癌寡转移的现状。

背景：胰腺癌是全球第七大死因，其中导管腺癌是最常见的肿瘤。半数患者在确诊时已出现转移：综述了可切除胰腺腺癌伴寡转移疾病的治疗方法，以概述现有证据：方法：使用MESH术语在PubMed/Medline、Clinical Key和Index Medicus进行文献检索，检索期为1993年至2022年：结果：胰腺导管腺癌肝转移或肺转移患者接受手术和化疗后，经过严格筛选的患者生存期更长：有关胰腺导管腺癌和寡转移患者手术治疗的证据有限，需要针对这两种情况进一步开展随机对照试验。结论：有关胰腺导管腺癌和寡转移患者手术治疗的证据还很有限，还需要对这两种情况进行进一步的随机对照试验，并制定有助于选择接受此类治疗的患者的标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cirugia Y Cirujanos 医学-外科

CiteScore

0.90

自引率

20.00%

发文量

207

审稿时长

6-12 weeks

期刊介绍： Cirugía y Cirujanoses exponente del desarrollo académico, científico, médico, quirúrgico y tecnológico en materia de salud en México y en el ámbito internacional. Es una revista bimestral, open access, revisada por pares, que publica en español y en inglés (traducido sin coste para los autores) artículos científicos originales, casos clínicos, artículos de revisión de interés general y cartas al editor. Los artículos se seleccionan y publican siguiendo un riguroso análisis, de acuerdo con los estándares internacionalmente aceptados. Sus espacios están abiertos a los académicos, así como a todo miembro de la comunidad médica que manifieste interés por utilizar este foro para publicar sus trabajos.